Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
September 20, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive...
Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023
September 09, 2023 20:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster presentation...
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
August 31, 2023 07:30 ET
|
Zevra Therapeutics; Acer Therapeutics Inc.
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization...
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
August 14, 2023 07:30 ET
|
Zevra Therapeutics
Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million...
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster
August 07, 2023 16:45 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) ("Zevra" or “the Company"), a rare disease company melding science, data, and patient need to create...
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
August 02, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference
July 19, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
June 13, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
May 10, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today...
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
May 09, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...